Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Xtant Medical Holdings (XTNT) over the last 11 years, with Q3 2025 value amounting to $3.0 million.

  • Xtant Medical Holdings' Non-cash Items rose 3190.33% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 3190.33%. This contributed to the annual value of $900000.0 for FY2024, which is 5748.61% down from last year.
  • Xtant Medical Holdings' Non-cash Items amounted to $3.0 million in Q3 2025, which was up 3190.33% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Xtant Medical Holdings' Non-cash Items registered a high of $3.0 million during Q2 2025, and its lowest value of $122614.0 during Q1 2021.
  • Moreover, its 5-year median value for Non-cash Items was $1.4 million (2023), whereas its average is $1.5 million.
  • Per our database at Business Quant, Xtant Medical Holdings' Non-cash Items skyrocketed by 44760.39% in 2021 and then crashed by 5748.61% in 2024.
  • Quarter analysis of 5 years shows Xtant Medical Holdings' Non-cash Items stood at $649042.0 in 2021, then soared by 102.54% to $1.3 million in 2022, then surged by 61.04% to $2.1 million in 2023, then plummeted by 57.49% to $900000.0 in 2024, then soared by 234.02% to $3.0 million in 2025.
  • Its Non-cash Items was $3.0 million in Q3 2025, compared to $3.0 million in Q2 2025 and $2.9 million in Q1 2025.